AbCellera Biologics Reports Q2 2026 Results

What Happened

• AbCellera Biologics Inc. (ABCL) filed a Form 8‑K on August 5, 2026 announcing its financial and operational results for the quarter ended June 30, 2026. The company furnished a press release with those results as Exhibit 99.1.
• In connection with its earnings call on August 5, 2026, AbCellera also furnished a corporate presentation as Exhibit 99.2 under Regulation FD. The filing is furnished (not “filed”) and is not subject to Section 18 liability or incorporation by reference except as stated.

Key Details

• Filing date: August 5, 2026; reporting period: quarter ended June 30, 2026.
• Exhibit 99.1: Press release announcing the quarter’s financial and operational results.
• Exhibit 99.2: Corporate presentation to be used on the August 5, 2026 earnings call (Regulation FD disclosure).
• Form 8‑K signed by CEO Carl L. G. Hansen, Ph.D.

Why It Matters

• Quarterly results and the accompanying presentation are primary sources for updated revenue, profitability, cash position, guidance or program updates—items that can affect AbCellera’s stock price and investor decisions.
• Investors should review the furnished press release and presentation for the specific financial figures and management commentary from the earnings call to assess performance and near‑term outlook.